Osimertinib-related liver injury with successful osimertinib rechallenge: A case report

Cheng, YL; Chang, WK; Yen, H; Peng, YJ; Chang, WC; Chang, PY

Chang, PY (通讯作者)，Tri Serv Gen Hosp, Div Hematol Oncol, Dept Internal Med, Natl Def Med Ctr, Taipei, Taiwan.;Chang, PY (通讯作者)，325,Sec 2,Cheng Gong Rd, Taipei 114, Taiwan.

THORACIC CANCER, 2022; 13 (15): 2271

Abstract

Osimertinib is approved as the first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor (EGFR) mutation and ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索